CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT

Executive Summary

CORTECH BRADYCOR SEPSIS TRIAL SHOWS NO SURVIVAL IMPROVEMENT in patients with systemic inflammatory response syndrome and presumed sepsis, the company reported July 21. Announcing results of its Phase II trial of the bradykinin antagonist, Cortech said "the primary analysis" of the trial results "did not demonstrate a clinically meaningful reduction in risk-adjusted 28-day survival." The 500-patient, 47-site study tested three dosing levels of three-day Bradycor infusion against placebo. "No safety concerns emerged" in the study, Cortech said.